He is right in away. It is just the opposite, the company wont release any press stating it was approached for a possible buyout.
Sarepta has also been shown to target the dystrophin biomarker with remarkable consistency -- although 12 patients may not seem like many, the fact that 100% of them showed biomarker response indicates extremely robust statistical reliability (oversimplification, but try to flip a coin heads 12 times in a row).
You are going to make me rich this year. Thank you for your service to Canada and its citizens for saving our behinds and bring bak BlackBerry to its glory days.